TY - JOUR
T1 - Longitudinal profile of circulating endothelial cells in post-acute coronary syndrome patients
AU - de Bakker, Marie
AU - Kraan, Jaco
AU - Akkerhuis, K. Martijn
AU - Oemrawsingh, Rohit
AU - Asselbergs, Folkert W.
AU - Hoefer, Imo
AU - Kardys, Isabella
AU - Boersma, Eric
N1 - Funding Information: This work was supported by the Dutch Heart Foundation (grant number 2007B012), the Netherlands Heart Institute-Interuniversity Cardiology Institute of the Netherlands (project number 071.01) and the Working Group on Cardiovascular Research Netherlands, all of which are non-commercial funding bodies. An unrestricted research grant was further obtained from Eli Lilly, the Netherlands We are grateful to Mai Van for her excellent technical assistance. Folkert Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Funding Information: We are grateful to Mai Van for her excellent technical assistance. Folkert Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Patients who have experienced an acute coronary syndrome (ACS) are at risk of a recurrent event, but their level of risk varies. Because of their close temporal relationship with vascular injury, longitudinal measurements of circulating endothelial cells (CECs) carry potential to improve individual risk assessment. Methods: We conducted an explorative nested case-control study within our multicenter, prospective, observational biomarker study (BIOMArCS) of 844 ACS patients. Following an index ACS, high-frequency blood sampling was performed during 1-year follow-up. CECs were identified using flow cytometric analyses in 15 cases with recurrent event, and 30 matched controls. Results: Cases and controls had a median (25th-75thpercentile) age of 64.1 (58.1-75.1) years and 80% were men. During the months preceding the endpoint, the mean (95%CI) CEC concentration in cases was persistently higher than in controls (12.8 [8.2-20.0] versus 10.0 [7.0-14.4] cells/ml), although this difference was non-significant (P = 0.339). In controls, the mean cell concentration was significantly (P = 0.030) lower in post 30-day samples compared to samples collected within one day after index ACS: 10.1 (7.5-13.6) versus 17.0 (10.8-26.6) cells/ml. Similar results were observed for CEC subsets co-expressing CD133 and CD309 (VEGFR-2) or CD106 (VCAM-1). Conclusion: Despite their close relation to vascular damage, no increase in cell concentrations were found prior to the occurrence of a secondary adverse cardiac event.
AB - Introduction: Patients who have experienced an acute coronary syndrome (ACS) are at risk of a recurrent event, but their level of risk varies. Because of their close temporal relationship with vascular injury, longitudinal measurements of circulating endothelial cells (CECs) carry potential to improve individual risk assessment. Methods: We conducted an explorative nested case-control study within our multicenter, prospective, observational biomarker study (BIOMArCS) of 844 ACS patients. Following an index ACS, high-frequency blood sampling was performed during 1-year follow-up. CECs were identified using flow cytometric analyses in 15 cases with recurrent event, and 30 matched controls. Results: Cases and controls had a median (25th-75thpercentile) age of 64.1 (58.1-75.1) years and 80% were men. During the months preceding the endpoint, the mean (95%CI) CEC concentration in cases was persistently higher than in controls (12.8 [8.2-20.0] versus 10.0 [7.0-14.4] cells/ml), although this difference was non-significant (P = 0.339). In controls, the mean cell concentration was significantly (P = 0.030) lower in post 30-day samples compared to samples collected within one day after index ACS: 10.1 (7.5-13.6) versus 17.0 (10.8-26.6) cells/ml. Similar results were observed for CEC subsets co-expressing CD133 and CD309 (VEGFR-2) or CD106 (VCAM-1). Conclusion: Despite their close relation to vascular damage, no increase in cell concentrations were found prior to the occurrence of a secondary adverse cardiac event.
KW - Circulating endothelial cells
KW - acute coronary syndrome
KW - atherosclerosis
KW - cardiovascular disease
KW - repeated measurements
KW - vascular injury
UR - http://www.scopus.com/inward/record.url?scp=85146658587&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/1354750X.2022.2162966
DO - https://doi.org/10.1080/1354750X.2022.2162966
M3 - Article
C2 - 36617894
SN - 1354-750X
VL - 28
SP - 152
EP - 159
JO - Biomarkers
JF - Biomarkers
IS - 2
ER -